Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

By W. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, J. O’Shaughnessy. Journal of Clinical Oncology, 2005

1,927 citations recorded by the source corpus.

Subfields: Biomaterials, Oncology, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/dabcc206a124f3250f4edd83946ffa0bba51c365

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Oncology

In Pharmaceutical Science

Citations in the corpus

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. (2011, background): “Several nanomedicines, including Doxil and Abraxane (diameters of 90 and 130 nm, respectively), have shown significant antitumour activity in highly vascularized tumours such as Kaposi's sarcoma and breast cancer, and have been approved for clinical us”
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. (2012, background): “In clinical studies, nab-paclitaxel was safe and increased ORR and time to progression in metastatic breast cancer compared with sb-paclitaxel, and it has shown activity in various other advanced solid tumors, including melanoma, pancreatic cancer, and NSCLC.(13-15) In particular, in a dose-finding ”
Therapeutic Nanoparticles for Drug Delivery in Cancer (2008, methodology): “1A], has been applied in the clinic for the treatment of metastatic breast cancer (7).”
Unraveling the mysteries of serum albumin—more than just a serum protein (2014, background): “Abraxane® has a greater therapeutic index than paclitaxel alone, being administered at higher doses with less toxicity and more efficacy than traditional paclitaxel therapy (Gradishar et al., 2005; Socinski et al., 2012; Iwamoto, 2013).”
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer (2009, neutral): “001), but it was easily managed.(71) The authors explained the increased antitumor activity of”
Size-Dependent Localization and Penetration of Ultrasmall Gold Nanoparticles in Cancer Cells, Multicellular Spheroids, and Tumors in Vivo (2012, neutral): “creased to some extent because of limited drug delivery into the tumor tissue.(1,2) The tumor microenvironment is structur-”